Fox Chase researchers win $1.4M DoD Prostate Cancer Health Equity Grant

TD Bank recommits $100K to MUSC Hollings’s SC AMEN program

TD Bank has committed $100,000 to support the MUSC Hollings Cancer Center’s SC AMEN program, a community outreach initiative that brings education, screenings, and health services assistance to Black men 40 to 69 years old in South Carolina.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Mushroom supplement may slow prostate cancer progression, City of Hope study finds

Researchers at City of Hope found that taking white button mushroom pills reduces a class of immune cells called myeloid-derived suppressor cells, which has been linked to cancer development and spread.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.

November 15, 2024

Vol.50 No.43

Clinical Trials & Tribulations

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment. xxx:more

Lorenzo Galluzzi joins Cancer Signaling and Microenvironment Research Program at Fox Chase

Lorenzo Galluzzi was named associate professor with tenure in the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center.

November 08, 2024

Vol.50 No.42

Clinical Roundup

Long-term risks from prostate cancer treatment detailed in new report

A new report says those considering PSA screening need such quantitative information on risks and benefits of treatment if they are to make truly informed decisions. Yet leading guidelines do not provide specific estimates of risk. The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after...

November 08, 2024

Vol.50 No.42

Fox Chase researchers win $1.4M DoD Prostate Cancer Health Equity Grant

YOU MAY BE INTERESTED IN

TD Bank recommits $100K to MUSC Hollings’s SC AMEN program

Mushroom supplement may slow prostate cancer progression, City of Hope study finds

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Lorenzo Galluzzi joins Cancer Signaling and Microenvironment Research Program at Fox Chase

Long-term risks from prostate cancer treatment detailed in new report

Renew today!

Subscriber content

Never miss an issue!

Login

Fox Chase researchers win $1.4M DoD Prostate Cancer Health Equity Grant

YOU MAY BE INTERESTED IN

TD Bank recommits $100K to MUSC Hollings’s SC AMEN program

Mushroom supplement may slow prostate cancer progression, City of Hope study finds

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

A study measures the long-term downside of prostate cancer screeningA paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Lorenzo Galluzzi joins Cancer Signaling and Microenvironment Research Program at Fox Chase

Long-term risks from prostate cancer treatment detailed in new report

Never miss an issue!

Login

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment